Show simple item record

dc.contributor.authorBordonaro, R.
dc.contributor.authorCalvo, A.
dc.contributor.authorAuriemma, A.
dc.contributor.authorHollebecque, A.
dc.contributor.authorRubovszky, G.
dc.contributor.authorSaunders, Mark P
dc.contributor.authorPápai, Z.
dc.contributor.authorPrager, G.
dc.contributor.authorStein, A.
dc.contributor.authorAndré, T.
dc.contributor.authorArgilés, G.
dc.contributor.authorCubillo, A.
dc.contributor.authorDahan, L.
dc.contributor.authorEdeline, J.
dc.contributor.authorLeger, C.
dc.contributor.authorCattan, V.
dc.contributor.authorFougeray, R.
dc.contributor.authorAmellal, N.
dc.contributor.authorTabernero, J.
dc.date.accessioned2021-09-30T11:56:06Z
dc.date.available2021-09-30T11:56:06Z
dc.date.issued2021en
dc.identifier.citationBordonaro R, Calvo A, Auriemma A, Hollebecque A, Rubovszky G, Saunders MP, et al. Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study. ESMO Open. 2021 Oct;6(5):100270.en
dc.identifier.pmid34547581en
dc.identifier.doi10.1016/j.esmoop.2021.100270en
dc.identifier.urihttp://hdl.handle.net/10541/624615
dc.description.abstractBackground: In preclinical studies trifluridine/tipiracil (FTD/TPI) plus oxaliplatin (Industriestrasse, Holzkirchen, Germany) sensitised microsatellite stable (MSS) metastatic colorectal cancer (mCRC) to anti-programmed cell death protein-1; the addition of oxaliplatin or bevacizumab (F Hoffmann- la ROCHE AG, Kaiseraugst, Switzerland) enhanced the antitumour effects of FTD/TPI. This study aimed to investigate the safety and efficacy of FTD/TPI plus oxaliplatin and either bevacizumab or nivolumab (Uxbridge business Park, Uxbridge, United Kingdom) in patients with mCRC who had progressed after at least one prior line of treatment. Patients and methods: In 14-day cycles, patients received FTD/TPI 35 mg/m2 (twice daily, days 1-5) plus oxaliplatin 85 mg/m2 (day 1), and, on day 1, either bevacizumab 5 mg/kg (cohort A) or nivolumab 3 mg/kg (cohort B). Patients in Cohort B had confirmed MSS status. Results: In total, 54 patients were enrolled: 37 in cohort A and 17 in cohort B. Recruitment in cohort B was stopped early due to the low response rate (RR) observed at interim analyses of efficacy. The most common adverse events (AEs) in cohort A were neutropenia/decreased neutrophils (75.7%), nausea (59.5%), vomiting (40.5%), diarrhoea (37.8%), peripheral sensory neuropathy (37.8%), fatigue (35.1%) and decreased appetite (35.1%). In cohort B, the most common AEs were neutropenia/decreased neutrophils (70.6%), diarrhoea (58.8%), nausea (47.1%), vomiting (47.1%), fatigue (47.1%), asthenia (41.2%), paraesthesia (41.2%), thrombocytopenia/decreased platelets (35.3%) and decreased appetite (35.3%). Confirmed objective RR was 17.1% in cohort A and 7.1% in cohort B; the corresponding values for median progression-free survival in the two cohorts were 6.3 and 6.0 months. Conclusion: FTD/TPI plus oxaliplatin and bevacizumab or nivolumab had an acceptable safety profile and demonstrated antitumour activity in previously treated patients with mCRC.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.esmoop.2021.100270en
dc.titleTrifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I studyen
dc.typeArticleen
dc.contributor.departmentAzienda Ospedaliera ARNAS Garibaldi, Catania, Italyen
dc.identifier.journalESMO Openen
dc.description.noteen]
refterms.dateFOA2021-10-13T08:48:13Z


Files in this item

Thumbnail
Name:
34547581.pdf
Size:
353.8Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record